Tosufloxacin p-Toluenesulfonate Hydrate

Research use only, not for human use.

Tosufloxacin p-Toluenesulfonate Hydrate is a fluoroquinolone antibacterial agent that is used to treat susceptible infections.

Tosufloxacin p-Toluenesulfonate Hydrate is a fluoroquinolone antibacterial agent that is used to treat susceptible infections.(In Vitro):Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens.(In Vivo):Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo.

Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens. Cell Viability Assay Cell Line:S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens Concentration:0.05-3.13 μg/mL Incubation Time:18 hours Result:Showed MIC90s (MICs for 90% of the isolates tested) ranging from 0.05 to 1.56 μg/mL for S. aureus, Staphylococcus epidermidis, streptococci, and enterococci.Showed MIC90s of 1.56, 3.13, and 0.20 μg/mL for Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens, respectively.

Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo. Animal Model:Male Slc:ICR mice infected with S. aureusDosage:1.27-2.15 mg/kg Administration:Oral gavage; 1.27-2.15 mg/kg; once Result:Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.0125 μg/mL.Animal Model:Male Slc:ICR mice infected with E. coli Dosage:0.16-0.30 mg/kg Administration:Oral gavage; 0.16-0.30 mg/kg; once Result:Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.0125 μg/mL.Animal Model:Male Slc:ICR mice infected with P. aeruginosa Dosage:7.66-13.39 mg/kg Administration:Oral gavage; 7.66-13.39 mg/kg; once Result:Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.Showed MIC value of 0.78 μg/mL.

Tosufloxacin Tosylate Hydrate | T-3262 Tosylate Hydrate | A-61827 tosylate hydrate

Others

Other Targets

Others

——

——

1400591-39-0

594.6

C26H25F3N4O7S

>98% (HPLC)

DMSO:33 mg/mL (55.5 mM)

CC1=CC=C(C=C1)S(=O)(=O)O.C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F.O

——

(-20℃)

With Ice Pack

≥ 2 years